BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
BiondVax Pharmaceuticals Ltd (NYSE:BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study…